IDO1 and glioblastoma: Notably, IDO1 was found to be highly expressed in GBM and CRC CSCs, where it plays a role in CSC-mediated immune evasion and thus could represent a promising therapeutic approach in cancer immunotherapy beyond traditional ICIs or CAR-T cell therapies [172, 306].